RegulatoryOfficial

INFARMED lifts suspension of Limeciclina Atral 408 mg capsules after bioequivalence shown

🇵🇹 INFARMED · Wed 18 Nov 2026

Portugal's regulator says the marketing authorisation for Limeciclina Atral 408 mg capsules is no longer suspended, following a variation that demonstrated bioequivalence.

INFARMED, the Portuguese medicines authority, has announced that the marketing authorisation (AIM) for Limeciclina Atral 408 mg capsules is no longer suspended. The notice is Circular Informativa No 104/CD/550.20.001, dated 13 November 2026 and published on 18 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: INFARMED ↗

Article written by VigiEye from the official source (INFARMED). AI-assisted; check the source before acting.